Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassay Screens for Clostridium difficile Infection

By LabMedica International staff writers
Posted on 26 Jul 2011
Rapid and accurate screening of patients with suspected Clostridium difficile infection is achieved with a new immunoassay.

The Prolisa C. More...
difficile glutamate dehydrogenase (GDH) enzyme immunoassay (EIA) utilizes a mouse monoclonal GDH antibody, and offers a high negative predictive value to rule out C. difficile infection quickly and easily.

A product of Pro-Lab Diagnostics’ (Toronto, Canada) the Prolisa C. difficile GDH EIA is a manual immunoassay, available in a 96-well test size, which has also been optimized and validated for the most widely used automated platforms. Reagents are supplied in larger volumes as standard, to accommodate automated systems and provide more flexibility, and are also available separately, with comprehensive lot-to-lot compatibility.

C. difficile infection can be identified more efficiently and economically by initially screening for GDH rather than by testing for toxins alone. Mark Reed, General Manager of Pro-Lab Diagnostics, explained, “Screening for GDH as a marker present in toxigenic and nontoxigenic strains of C. difficile followed by tests for toxin A or toxin B on GDH-positive samples, is an easy, quick, and cost-effective way to test for C. difficile infection, as several UK customers are already finding.”

Related Links:
Pro-Lab Diagnostics



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.